Valsartan

Valsartan is a synthetic small-molecule drug classified as an angiotensin II receptor blocker, a family of agents also called ARBs or sartans that are used chiefly for cardiovascular disease ^[1]. It selectively targets the type 1 angiotensin II receptor and, unlike the older ACE inhibitors, blocks the hormone at its receptor rather than preventing the hormone from forming ^[1]. The drug is taken by mouth and is marketed both on its own and within combination products.

Its principal uses are the treatment of high blood pressure and of chronic heart failure, and it is also given to improve survival in people who have had a heart attack accompanied by weakened left-ventricular function ^[1][2]. In hypertension it is regarded as a suitable first-line option for many patients ^[3]. Several large randomized trials have shaped its role: the Val-HeFT study examined adding valsartan to standard heart-failure therapy ^[1], the VALUE trial compared valsartan-based and amlodipine-based regimens in high-risk hypertensive patients ^[3], and the PARADIGM-HF trial showed that the valsartan-containing combination sacubitril/valsartan was superior to enalapril in heart failure with reduced ejection fraction ^[2].

Valsartan was patented around 1990 and came into medical use in 1996 ^[1]. It is available as single-ingredient tablets and in fixed-dose combinations, including with the diuretic hydrochlorothiazide, with the calcium-channel blocker amlodipine, and with the neprilysin inhibitor sacubitril for heart failure ^[1][2]. It remains one of the more commonly prescribed medicines in the United States.

Valsartan is a prescription-only medicine in the United States, the United Kingdom and Australia ^[1]. Beginning in 2018, regulators including the European Medicines Agency and the U.S. Food and Drug Administration recalled numerous batches of valsartan after nitrosamine impurities such as N-nitrosodimethylamine (NDMA) and, later, N-nitrosodiethylamine (NDEA) were detected; these substances are considered probable human carcinogens, and the contamination was traced to manufacturing processes at certain active-ingredient suppliers. The episode prompted tighter controls over how sartan medicines are produced.

Valsartan is prescription only and generally well tolerated. Its most serious caution is that it must be avoided in pregnancy because it can harm the fetus. It can raise blood potassium, especially with potassium supplements, spironolactone, or ACE inhibitors, and it can lower blood pressure enough to cause dizziness, particularly early or when dehydrated. Kidney function and potassium are checked after starting or increasing the dose. It should not be combined with the renin inhibitor aliskiren in people with diabetes, and NSAIDs can blunt its effect and stress the kidneys. Some past batches were recalled over a manufacturing impurity, though that was a quality issue rather than a property of the drug itself.

The interactions that cause admissions all involve potassium and the kidney. Combining valsartan with potassium-sparing diuretics, potassium supplements, salt substitutes or trimethoprim raises the risk of hyperkalemia, because blocking angiotensin II lowers aldosterone and with it renal potassium excretion.

Dual blockade of the renin-angiotensin system is the pairing regulators moved against. Adding an ACE inhibitor or aliskiren increased hyperkalemia, hypotension and renal failure without an offsetting benefit in the ONTARGET and ALTITUDE trials, and the aliskiren combination is contraindicated in diabetes.

NSAIDs blunt the antihypertensive effect and, alongside a diuretic, complete the triple combination associated with acute kidney injury in volume-depleted or older patients. Lithium concentrations rise when an angiotensin receptor blocker is added, through reduced renal clearance, and lithium toxicity has been reported.

Checking a whole stack? Run it through interactions + stacks.

Valsartan is an angiotensin II receptor blocker developed by Ciba-Geigy, one of the Swiss companies that merged to form Novartis, as a follow-on to the first-in-class ARB losartan. It was designed to selectively block the type 1 angiotensin II receptor, lowering blood pressure and easing cardiac workload without raising bradykinin levels, which is why the class avoids the dry cough associated with ACE inhibitors. The drug was approved by the United States Food and Drug Administration in 1996 and marketed as Diovan, going on to become one of the most widely prescribed antihypertensives worldwide.

Valsartan accumulated an unusually deep clinical-trial pedigree; Val-HeFT established its benefit in heart failure, VALIANT showed it was as effective as captopril after myocardial infarction, and VALUE evaluated it in high-risk hypertension. It later became the angiotensin-receptor component of sacubitril/valsartan, the neprilysin-inhibitor combination that outperformed enalapril in the landmark PARADIGM-HF heart-failure trial.

Valsartan is a highly respected cardiovascular medicine, valued for its efficacy, tolerability, and the remarkable weight of evidence supporting it. Clinicians appreciate that it controls blood pressure and protects the heart while avoiding the cough that limits ACE inhibitors for many patients, and its record across major outcome trials in heart failure, post-infarction care, and hypertension gives prescribers considerable confidence.

Its inclusion in sacubitril/valsartan, a combination that reshaped modern heart-failure treatment, further cemented its standing. Beyond the cardiovascular field, preclinical work has hinted at an intriguing neuroprotective angle, with valsartan lowering brain amyloid-beta and improving spatial learning in a mouse model of Alzheimer disease, a finding that remains exploratory but adds to scientific interest. Taken together, valsartan is regarded as a dependable, extensively validated drug with a well-characterized safety profile.